<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5514">
  <stage>Registered</stage>
  <submitdate>29/08/2008</submitdate>
  <approvaldate>29/08/2008</approvaldate>
  <nctid>NCT00745043</nctid>
  <trial_identification>
    <studytitle>Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study</studytitle>
    <scientifictitle>Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?</scientifictitle>
    <utrn />
    <trialacronym>BOLD</trialacronym>
    <secondaryid>NTX/05/04/035</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - bronchodilator response

Placebo Comparator: R302 - Daily placebo capsules

Active Comparator: R303 - Daily metoprolol 95mg capsules

Active Comparator: R304 - Daily propranolol 80mg capsules

Active Comparator: Open Label - Daily Metoprolol 190mg capsules


Treatment: drugs: bronchodilator response


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bronchodilator response to salbutamol after beta-blockers</outcome>
      <timepoint>7-10 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incremental Shuttle Walk Test Result after taking beta-blockers</outcome>
      <timepoint>7-10 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinical diagnosis of COPD

          -  &gt; 40 years of age

          -  &gt; 15 pack year smoking history</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Contra-indication to beta-blocker use

          -  Severe COPD FEV1 &lt; 30% or 1 L

          -  Not responsive the methacholine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>11</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Waikato Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Waikato Hospital Research Fund</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These
      are very common conditions and many patients have both diseases. Beta-blocker drugs are
      extensively used in the treatment of angina, high blood pressure and after heart attacks to
      decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness
      and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in
      COPD patients as they may make the breathlessness worse, but it has now been established that
      they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the
      body and the investigators do not know if they can work together or if they would cancel each
      other out. The investigators also do not know which of the different types of beta-blockers
      now available are better for COPD patients. This study will investigate what happens to the
      airways of people taking both of these drugs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00745043</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bob Hancox, MD FRACP</name>
      <address>Waikato Hospital Research Unit</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>